Payment overview · 2025
General Payments
$594.53
37 reported records · 13 companies
Healthcare provider profile · identity verified
Stephen R Cannon, MD
Allopathic & Osteopathic Physicians|Family Medicine · CROWLEY, LA · NPI 1083777908
Verified facts
What the public records show
CMS Open Payments records show Stephen R Cannon, MD received $594.53 in general payments during 2025 across 37 reported records.
ABBVIE INC. accounted for 30.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $183.00 | 30.8% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $86.59 | 14.6% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $66.96 | 11.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $64.16 | 10.8% | 4 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $35.13 | 5.9% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $31.72 | 5.3% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.60 | 4.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.21 | 3.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.48 | 3.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.19 | 3.1% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $16.00 | 2.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.94 | 2.7% | 1 | 2025 |
| CorVista Health, Inc. | Unresolved — no canonical attribution shown | $13.55 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $594.53 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $118.93 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $117.81 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $66.96 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $55.11 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $49.15 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.81 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.85 | 2 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $35.13 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $31.48 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $25.60 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.19 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| CorVista System Normalized: corvista system |
Device | CorVista Health, Inc. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 349 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 273 | 54 |
| Gabapentin | Gabapentin | 267 | 40 |
| Metformin Hcl | Metformin Hcl | 265 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 257 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 245 | 47 |
| Omeprazole | Omeprazole | 236 | 47 |
| Atorvastatin Calcium | Atorvastatin Calcium | 230 | 47 |
| Quetiapine Fumarate | Quetiapine Fumarate | 206 | 39 |
| Tramadol Hcl | Tramadol Hcl | 190 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 184 | 43 |
| Pioglitazone Hcl | Pioglitazone Hcl | 177 | 40 |
| Montelukast Sodium | Montelukast Sodium | 174 | 30 |
| Sertraline Hcl | Sertraline Hcl | 161 | 27 |
| Lisinopril | Lisinopril | 155 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 30 |
| Furosemide | Furosemide | 146 | 34 |
| Memantine Hcl | Memantine Hcl | 138 | 22 |
| Trazodone Hcl | Trazodone Hcl | 137 | 23 |
| Meloxicam | Meloxicam | 127 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 21 |
| Clonazepam | Clonazepam | 119 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 117 | 17 |
| Carvedilol | Carvedilol | 116 | 25 |
| Simvastatin | Simvastatin | 110 | 19 |
| Alendronate Sodium | Alendronate Sodium | 107 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 103 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 13 |
| Potassium Chloride | Potassium Chloride | 100 | 22 |
| Primidone | Primidone | 91 | 13 |
| Finasteride | Finasteride | 89 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 88 | 21 |
| Valsartan | Valsartan | 84 | 17 |
| Alprazolam | Alprazolam | 82 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 78 | 12 |
| Ozempic | Semaglutide | 78 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 75 | 12 |
| Celecoxib | Celecoxib | 71 | 15 |
| Januvia | Sitagliptin Phosphate | 71 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 70 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 69 | 30 |
| Metformin Hcl Er | Metformin Hcl | 67 | 14 |
| Prednisone | Prednisone | 67 | 45 |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | 12 |
| Losartan Potassium | Losartan Potassium | 66 | 14 |
| Clonidine Hcl | Clonidine Hcl | 64 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 63 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 15 |
| Cefdinir | Cefdinir | 60 | 47 |
| Donepezil Hcl | Donepezil Hcl | 60 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | suppressed |
| Lactulose | Lactulose | 60 | 15 |
| Spironolactone | Spironolactone | 56 | 13 |
| Xarelto | Rivaroxaban | 56 | suppressed |
| Glimepiride | Glimepiride | 54 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | suppressed |
| Risperidone | Risperidone | 51 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | suppressed |
| Allopurinol | Allopurinol | 47 | suppressed |
| Estradiol | Estradiol | 47 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 19 |
| Famotidine | Famotidine | 46 | suppressed |
| Minoxidil | Minoxidil | 46 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Eliquis | Apixaban | 42 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Fluconazole | Fluconazole | 40 | 25 |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 23 |
| Ezetimibe | Ezetimibe | 39 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 37 | suppressed |
| Pregabalin | Pregabalin | 37 | 12 |
| Jardiance | Empagliflozin | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 27 |
| Lorazepam | Lorazepam | 35 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Gemfibrozil | Gemfibrozil | 33 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 32 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 17 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 17 |
| Olanzapine | Olanzapine | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Niacin Er | Niacin | 20 | suppressed |
| Nystatin | Nystatin | 20 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 15 |
| Carisoprodol | Carisoprodol | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Jantoven | Warfarin Sodium | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Butrans | Buprenorphine | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | 12 |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Savella | Milnacipran Hcl | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $594.53 · 37 records | ABBVIE INC. | ABRYSVO, BREZTRI, CAPLYTA, COMIRNATY, CONTRAVE, Cologuard Collection Kit, CorVista System, FARXIGA, IBSRELA, JARDIANCE, MOUNJARO, PREVNAR 20, QULIPTA, RELISTOR, TRULANCE, UBRELVY, VOQUEZNA, VRAYLAR, WATCHMAN FLX, Wegovy, XIFAXAN, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error